Beam Therapeutics Liabilities 2025

Beam Therapeutics Aktienanalyse

What does Beam Therapeutics do?

Beam Therapeutics Inc. is a leading company in genome editing and was founded in 2018. The company is headquartered in Cambridge, Massachusetts, USA, and aims to develop and bring innovative genome editing technologies to the market. Beam Therapeutics' business model is based on developing groundbreaking technologies that improve and simplify genome editing in living cells. These technologies are used in medicine, agriculture, and other industries to cure diseases, increase crop yields, and improve quality of life. Beam Therapeutics is led by an experienced and competent team composed of leading scientists, engineers, and businesspeople in the industry. The company collaborates closely with industry and academic partners to develop innovative solutions for genome editing. Beam Therapeutics has several business units focused on the development of genome editing technologies and products. One of these business units is the development of CRISPR technologies (Clustered Regularly Interspaced Short Palindromic Repeats), which allow for precise and effective modification of DNA. Beam Therapeutics employs Prime Editors, a new technology that enables the removal, insertion, or replacement of specific DNA sequences. Another important business area for Beam Therapeutics is the development of novel gene therapy products. This involves repairing or removing disease-causing genes in the body to accelerate or even achieve complete recovery. The gene therapy products being developed by Beam Therapeutics have the potential to save lives and provide a long-term solution for certain diseases such as cancer, viral infections, and specific genetic disorders. The company collaborates closely with universities, hospitals, and other institutions to drive the development of gene therapy products. Beam Therapeutics strives to revolutionize the gene therapy industry and improve the treatment of diseases through genome editing. Overall, Beam Therapeutics has an impressive track record and has experienced strong growth in recent years. The company has successfully completed multiple funding rounds to advance its research and development and has hired many talented employees to realize its vision. In summary, Beam Therapeutics is a medical technology company specializing in the development of groundbreaking genome editing technologies and products. The company aims to revolutionize genome editing in medicine, agriculture, and other industries and have a positive impact on people's lives. Beam Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Beam Therapeutics's Liabilities

Beam Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Beam Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Beam Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Beam Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Beam Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Beam Therapeutics stock

What is the level of liabilities of Beam Therapeutics this year?

Beam Therapeutics has a debt balance of 478.39 M USD this year.

What were the liabilities of Beam Therapeutics compared to the previous year?

The liabilities of Beam Therapeutics have increased by -21.34% dropped compared to the previous year.

What are the consequences of high debt for investors of Beam Therapeutics?

High liabilities can pose a risk for investors of Beam Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Beam Therapeutics?

Low liabilities mean that Beam Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Beam Therapeutics affect the company?

An increase in liabilities of Beam Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Beam Therapeutics affect the company?

A decrease in the liabilities of Beam Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Beam Therapeutics?

Some factors that can influence the liabilities of Beam Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Beam Therapeutics so important for investors?

The liabilities of Beam Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Beam Therapeutics take to modify the liabilities?

To change its liabilities, Beam Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Beam Therapeutics pay?

Over the past 12 months, Beam Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Beam Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Beam Therapeutics?

The current dividend yield of Beam Therapeutics is .

When does Beam Therapeutics pay dividends?

Beam Therapeutics pays a quarterly dividend. This is distributed in the months of December, March, June, March.

How secure is the dividend of Beam Therapeutics?

Beam Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Beam Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Beam Therapeutics located?

Beam Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Beam Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Beam Therapeutics from 3/3/2014 amounting to 0.225 USD, you needed to have the stock in your portfolio before the ex-date on 2/4/2014.

When did Beam Therapeutics pay the last dividend?

The last dividend was paid out on 3/3/2014.

What was the dividend of Beam Therapeutics in the year 2024?

In the year 2024, Beam Therapeutics distributed 0 USD as dividends.

In which currency does Beam Therapeutics pay out the dividend?

The dividends of Beam Therapeutics are distributed in USD.